Your browser doesn't support javascript.
loading
Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government.
van der Pol, Karel H; Aljofan, Mohamad; Blin, Olivier; Cornel, Jan H; Rongen, Gerard A; Woestelandt, Aurélie-Gaëlle; Spedding, Michael.
Afiliación
  • van der Pol KH; Department of Internal Medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Aljofan M; Department of Biomedical Science, Nazarbayev University School of Medicine, Nur-Sultan, Kazakhstan.
  • Blin O; National Laboratory Astana, Nazarbayev University, Astana, 010000, Kazakhstan.
  • Cornel JH; Institut de Neurosciences des Systèmes, Aix Marseille Université, Inserm UMR 1106, Marseille, France.
  • Rongen GA; Department of Cardiology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Woestelandt AG; Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands.
  • Spedding M; Department of Internal Medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. Gerard.Rongen@radboudumc.nl.
Appl Health Econ Health Policy ; 21(6): 831-840, 2023 11.
Article en En | MEDLINE | ID: mdl-37398987
Drug repurposing is the process of identifying a new use for an existing drug or active substance in an indication outside the scope of the original indication. Drug repurposing has important advantages including reduced development time and costs, and potentially large societal healthcare cost savings. However, current generic drug repurposing research faces a number of challenges in obtaining research funds. Furthermore, regardless of the success of a repurposing trial, commercial parties often lack interest in pursuing marketing authorisation for financial reasons, and academic researchers lack the knowledge, time and funding. Therefore, the new indication of a repurposed drug often does not make it 'on label'. We propose a large increase in public funding for generic drug repurposing research, including funds for the marketing authorisation process when a trial is successful, and a reduction in the regulatory burden of the marketing authorisation process for repurposed generic drugs.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicamentos Genéricos / Reposicionamiento de Medicamentos Límite: Humans Idioma: En Revista: Appl Health Econ Health Policy Asunto de la revista: SAUDE PUBLICA / SERVICOS DE SAUDE Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Nueva Zelanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicamentos Genéricos / Reposicionamiento de Medicamentos Límite: Humans Idioma: En Revista: Appl Health Econ Health Policy Asunto de la revista: SAUDE PUBLICA / SERVICOS DE SAUDE Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Nueva Zelanda